Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The RAPIID program focuses on developing an innovative, comprehensive resuscitation system designed to enhance far-forward trauma care by providing a capability comparable or superior to stored whole blood without relying on cold storage or donor logistics. This system will consist of a blood analog system made up of sequentially administered components, along with rugged delivery methods, point-of-care diagnostics, and clinical practice guidelines to support use in demanding environments. The program aims to advance these components through high technology readiness levels, targeting advanced development stages including Phase II clinical trials for blood analogs and clinical studies for devices and diagnostics, while also formulating regulatory and commercialization plans to ensure long-term viability. This solicitation specifically requests proposals for Phase 1 efforts related to Task Areas 1 and 2, with a deadline for submission on June 24, 2026. Managed by the Defense Advanced Research Projects Agency under the Department of Defense, the contract emphasizes scalable and field-ready solutions for trauma resuscitation. Interested parties can find further information and submit their proposals through the official government portal, with contact support provided via a designated program email.
General Info
Agency
NAICS
Place of Performance
VASet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.